Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders... Show more
Opus Genetics is a clinical-stage ophthalmic biopharmaceutical company focused on gene therapies designed to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and related retinal and refractive disorders. The company's positioning centers on targeting genetically defined, high-unmet-need conditions where a validated therapeutic target can support a focused development pathway and, in many cases, orphan-drug regulatory advantages.
By advancing parallel programs in LCA5-associated retinal degeneration, BEST1-related disease, and RDH12-related disease, Opus is building a diversified rare-disease pipeline rather than relying on a single asset. This breadth reduces single-program risk while potentially creating a franchise in ophthalmic gene therapy. However, as a clinical-stage company with modest revenue, the firm remains dependent on disciplined capital allocation, successful trial execution, and its ability to convert clinical data into regulatory and commercial milestones.
Several events could influence investor sentiment over the coming quarters. The most consequential is the anticipated first-quarter 2027 topline readout for OPGx-BEST1, where efficacy and safety data from the high-dose cohort could validate the platform's therapeutic potential. Separately, the initiation of dosing in the fully enrolled OPGx-LCA5 Phase 3 trial during the fourth quarter of 2026 marks a step toward registrational data. The FDA's IND clearance for OPGx-RDH12, with Phase 1/2 dosing planned for late 2026, adds a third clinical-stage program.
On the commercial and financing side, the milestone payment triggered by Viatris following FDA approval of phentolamine ophthalmic solution for presbyopia provides a potential non-dilutive cash source. Analyst sentiment remains constructive: consensus data indicates a Strong Buy rating profile with an average 12-month price target that implies significant upside relative to recent prices, though targets should be read as external analyst expectations rather than company guidance. Continued rating changes or price-target revisions ahead of the OPGx-BEST1 data readout could further shape the growth catalyst narrative.
Opus Genetics operates within the broader gene therapy and rare-disease biopharmaceutical sector, which is sensitive to both scientific progress and financial conditions. Higher-for-longer interest rates tend to compress valuations for pre-revenue biotechnology companies, since investors discount future cash flows more heavily; a more accommodative rate environment could conversely support the sector. Inflation and healthcare pricing pressures also influence reimbursement and payer dynamics, though rare ophthalmic diseases generally carry strong orphan-drug economics.
Regulatory climate is a central macro variable. A predictable FDA review environment and continued support for gene therapy approvals would benefit Opus's pipeline, while manufacturing complexity and durability-of-response requirements remain structural challenges across the field. Technology adoption in ophthalmic gene therapy is advancing, but competition from alternative modalities—including gene editing and other retinal therapies—could reshape the competitive landscape over time.
Tickeron's Trend Prediction Engine is an AI-powered forecasting tool that helps traders assess whether a stock, ETF (exchange-traded fund), or other asset may move bullish, bearish, or sideways over the next week or month. Designed to help users spot developing trends, evaluate possible breakouts or reversals, and explore predictions across a wide range of tradable instruments, the platform offers searchable prediction categories, historical context, and alert-oriented functionality. For those monitoring IRD's evolving story, the engine provides an additional, data-driven perspective worth exploring alongside fundamental research.
Looking toward 2026 and beyond, Opus Genetics' trajectory will likely be defined by its ability to translate clinical milestones into durable value. Near term, the OPGx-BEST1 data readout and OPGx-LCA5 dosing initiation represent the clearest inflection points, while the RDH12 program extends the pipeline's runway. Cost structure and margin sustainability remain secondary to clinical execution at this stage, but R&D (research and development) efficiency and disciplined G&A (general and administrative) spending will matter as the company scales.
Longer term, market expansion opportunities in genetically defined retinal diseases, potential partnership economics, and the evolution of gene therapy reimbursement will shape sentiment. Competitive threats from emerging gene-editing approaches and alternative ophthalmic therapies could intensify, while regulatory developments and capital allocation priorities—including any future financing—will influence the risk profile. Consensus analyst expectations remain optimistic, but investors should weigh these external price targets and ratings against the inherent binary risk of clinical-stage biotechnology.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| GCOR | 39.89 | 0.27 | +0.68% |
| Goldman Sachs Access U.S. Aggregate Bond ETF (GCOR) | |||
| WEAT | 21.44 | -0.03 | -0.14% |
| Teucrium Wheat Fund (WEAT) | |||
| XSHD | 12.40 | -0.11 | -0.88% |
| Invesco S&P SmallCap High Dividend Low Volatility ETF (XSHD) | |||
| VNQ | 92.56 | -0.91 | -0.97% |
| Vanguard Real Estate ETF (VNQ) | |||
| MCHS | 31.26 | -1.07 | -3.31% |
| Matthews China Innovators Active ETF (MCHS) | |||
A.I.dvisor indicates that over the last year, IRD has been loosely correlated with ARRY. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if IRD jumps, then ARRY could also see price increases.
| Ticker / NAME | Correlation To IRD | 1D Price Change % | ||
|---|---|---|---|---|
| IRD | 100% | -2.21% | ||
| ARRY - IRD | 35% Loosely correlated | -9.67% | ||
| PRME - IRD | 35% Loosely correlated | -7.55% | ||
| DMAC - IRD | 34% Loosely correlated | +2.87% | ||
| FDMT - IRD | 33% Loosely correlated | -4.57% | ||
| SRPT - IRD | 33% Loosely correlated | -5.93% | ||
More | ||||
a clinical stage biopharmaceutical company, which engages in the research and development of oncology therapeutics
Industry Biotechnology
The RSI Indicator for IRD moved out of oversold territory on October 27, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 26 similar instances when the indicator left oversold territory. In 24 of the 26 cases the stock moved higher. This puts the odds of a move higher at 90%.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The Moving Average Convergence Divergence (MACD) for IRD just turned positive on November 03, 2026. Looking at past instances where IRD's MACD turned positive, the stock continued to rise in 37 of 50 cases over the following month. The odds of a continued upward trend are 74%.
Following a +1.76% 3-day Advance, the price is estimated to grow further. Considering data from situations where IRD advanced for three days, in 215 of 260 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
IRD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on November 20, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IRD as a result. In 92 of 107 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IRD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
The Aroon Indicator for IRD entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 5 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-26.779) is normal, around the industry mean (3.596). P/E Ratio (-3.240) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (46.083) is also within normal values, averaging (443.347).
The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. IRD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 86 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IRD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.